

STRUCTURE OF ASPARAGAMINE A, A NOVEL POLYCYCLIC ALKALOID FROM ASPARAGUS RACEMOSUS

Toshikazu SEKINE,^{*, a} Nobuaki FUKASAWA,^a Yumi KASHIWAGI,^a Nijisiri RUANGRUNGSI,^b and Isamu MURAKOSHI^a

Faculty of Pharmaceutical Sciences, Chiba University,^a Yayoi-cho 1-33, Inage-ku, Chiba 263, Japan and Faculty of Pharmaceutical Sciences, Chulalongkorn University,^b Bangkok 10330, Thailand

A new cage-type alkaloid, asparagamine A (**1**), was isolated from the roots of *Asparagus racemosus* Willd. (Liliaceae). The relative stereostructure was elucidated by spectroscopic, chemical and single crystal X-ray analyses as a novel polycyclic pyrrolizidine derivative.

KEYWORDS alkaloid; asparagamine A; *Asparagus racemosus*; Liliaceae; polycyclic pyrrolizidine; cage compound

In our previous papers, we have reported the isolation and characterization of several new biologically active products, such as camelliaside A-C,^{1, 2)} L-methionine S(S)-sulfoximine³⁾ and entadamide A-C,^{4, 5)} from Asian tropical medicinal plants and crude drugs. As a series of this program, the present paper deals with the isolation and the structural elucidation of a new alkaloid (**1**) named asparagamine A from the roots of a Thai medicinal plant, *Asparagus racemosus* Willd. (Liliaceae). *A. racemosus* is a woody small plant growing in Southeast Asia, India, Australia and Africa, and the root has been used as a stimulant, restorative and demulcent in India and Thailand.⁶⁾

From 75% EtOH extracts of the dried roots of *A. racemosus*, **1** was isolated as a major compound (0.13 % / dry wt.), positive to Dragendorff's and I₂-platinate reagents, by chromatographic (silica gel) separation. Compound **1** is a colorless prism, mp 180°C (ether), [α]_D + 202.5° (MeOH), and its molecular formula C₂₂H₂₇NO₅ [observed *m/z* 385.1895 (M)⁺, calcd. *m/z* 385.1889] was confirmed by a high-resolution electron impact mass spectrometry (HR-EI-MS)⁷⁾. The IR (ν_{max} 1750, 1620, 1015 cm⁻¹ [KBr]) and UV (λ_{max} 294.4 nm [MeOH]) spectra indicated the presence of an α, β-unsaturated lactone structure in the molecule.

The ¹H-NMR spectrum (CDCl₃)⁸⁾ of **1** exhibited signals for three methyl [δ 0.93 (t), 1.32 (d) and 2.01 (s)] groups, one methoxyl [δ 4.08 (s)] group and a set of olefinic hydrogens [δ 5.44 (d) and 5.71 (dt)]. The ¹³C-NMR spectrum (CDCl₃) of **1** showed signals of 22 carbons including one carbonyl (δ 169.7), one ketal carbon (δ 112.7), and three sets of olefinic carbons (δ 126.4/133.2, 148.3/127.7 and 162.8/98.3) with a substituted pyrrolizidine ring (Fig. 1). Further two-dimensional (2D)-NMR analysis of **1** and its *N*-oxide (**2**)⁹⁾, obtained by an usual *N*-oxidation with *m*-chloroperbenzoic acid, by changing the solvent to benzene-*d*₆, allowed us to deduce a pyrrolizidine skeleton with an additional substituent at C-8 and a fused-ring structure for **1** as shown in Fig. 1. The ¹H detected heteronuclear multiple bond connectivity (HMBC) spectra (*J*=8 Hz) of **1** and **2** corroborated the proposed structure (Fig. 1).





Fig. 1. Structure and Significant Two and Three Bond Correlation Revealed by HMBC Spectra of 1

In order to establish the stereochemical configurations of each chiral center in the polycyclic rings of 1, a single crystal X-ray diffraction analysis¹⁰⁾ was undertaken on a crystal obtained from ether. The molecular structure and relative stereochemistry of 1 was unequivocally established as shown in Fig. 2.

Fig. 2. ORTEP View of 1



Numerous macrocyclic types of pyrrolizidine alkaloid have been isolated from several pyrrolizidine-bearing plants.¹³⁾ To our knowledge, asparagine A (1) is the first example that has a complicated polycyclic structure fused with a pyrrolizidine ring. Its cage-type structure seems to be extremely unique and interesting from the biosynthetic and pharmacological points of view. In fact, asparagine A in dose form 10 to 100 $\mu\text{g}/\text{ml}$ showed anti-tumor activity on several tumor models *in vitro*

in a dose dependent manner. On the other hand, we are trying to discover other pharmacological activities in other models. The results will be reported in a subsequent paper.

ACKNOWLEDGEMENTS We are very grateful to Dr. K. Kawai, Dr. S. Ohmiya and Dr. K. Higashiyama (Hoshi University), and Dr. M. Shiro (Rigaku Corporation) for the measurement and for cordial advice on X-ray analysis.

REFERENCES AND NOTES

- 1) T. Sekine, J. Arita, A. Yamaguchi, K. Saito, S. Okonogi, N. Morisaki, S. Iwasaki, I. Murakoshi, *Phytochemistry*, **30**, 991 (1991).
- 2) T. Sekine, Y. Arai, F. Ikegami, Y. Fujii, S. Shindo, T. Yanagisawa, Y. Ishida, S. Okonogi, I. Murakoshi, *Chem. Pharm. Bull.*, **41**, 1185 (1993).
- 3) I. Murakoshi, T. Sekine, K. Maeshima, F. Ikegami, K. Yoshinaga, Y. Fujii, S. Okonogi, *Chem. Pharm. Bull.*, **41**, 388 (1993).
- 4) F. Ikegami, T. Sekine, M. Aburada, Y. Fujii, Y. Komatsu, I. Murakoshi, *Chem. Pharm. Bull.*, **37**, 1932 (1989).
- 5) F. Ikegami, T. Sekine, S. Duangteraprecha, N. Matsushita, N. Matsuda, N. Ruangrunsi, I. Murakoshi, *Phytochemistry*, **28**, 881 (1989).
- 6) a) I. H. Burkill, *A Dictionary of the Economic Products of the Malay Peninsula*, (1966), Governments of Malaysia and Singapore, pp. 264; b) S. Pongboonrod, *Mai Tet Muang Thai*, Kasembunnakich Press (Bangkok), 1950, pp. 612.
- 7) EI-MS of 1 m/z (rel. int.) 385 [M]⁺ (64.7), 370 (5.7), 356 (13.0), 231 (14.4), 230 (17.5), 203 (12.3), 202 (44.6), 188 (6.5), 174 (6.8), 162 (92.9), 161 (38.1), 160 (100), 134 (14.7), 120 (11.5), 106 (12.1), 83 (10.1), 69 (8.0), 55 (7.0).
- 8) ¹H-NMR (500MHz, CDCl₃) δ 5.71 (1H, dt, J = 15.5, 6.4 Hz, H-21), 5.44 (1H, d, J = 15.5 Hz, H-20), 4.14 (1H, brs, H-7), 4.08 (3H, s, H-18), 3.45 (1H, brs, H-5), 3.04 (1H, m, H-11), 3.03 (1H, m, H-3), 2.93 (1H, m, H-3), 2.79 (1H, d, J = 5.9Hz, H-1), 2.01 (3H, s, H-19), 2.01 (2H, m, H-22), 1.89 (1H, d, J = 12.2 Hz, H-6), 1.82 (1H, m, H-2), 1.77 (1H, m, H-12), 1.74 (1H, m, H-6), 1.73 (1H, m, H-2), 1.32 (3H, d, J = 6.4 Hz, H-17), 0.93 (3H, t, J = 7.5 Hz, H-23).
- 9) colorless syrup, $[\alpha]_D + 146.5^\circ$ (MeOH), HR-FAB-MS m/z 402.1919 [M+H]⁺ (Calcd. for C₂₂H₂₈NO₆, 402.1917).
- 10) Crystal data : C₂₂H₂₇NO₅, orthorhombic, space group P2₁2₁2₁, a=9.841 (1), b=27.067 (1), c=7.768 (1) Å, V=2069.8 (4) Å³, Z=4, D_c=1.237 g cm⁻³, μ(CuKα)=7.14cm⁻¹, F(000)=824.000, R=0.052, 1287 unique reflections. The structure was solved by the direct method¹¹⁾ and expanded using Fourier techniques.¹²⁾
- 11) by SHELXS86: G. M. Sheldrick, "Crystallographic Computing 3", ed. by G. M. Sheldrick, C. Kruger and R. Goddard, Oxford University Press, 1985, pp.175.
- 12) by DIRDIF92: P. T. Beurkens, G. Admiraal, G. Beurkens, W. P. Bosmann, S. Garcia-Granda, R. O. Gould, J. M. M. Smits, C. Smykalla, "The DIRDIF program system, Technical Report of the Crystallography Laboratory", University of Nijmegen, The Netherlands, 1992.
- 13) a) J. T. Wrobel, "The Alkaloids", Vol 26, ed. by A. Brossi, Academic Press (London), 1985, pp. 327; b) F. L. Warren, "The Alkaloids", Vol. 12, ed. by R. H. F. Manske, Academic Press (London), 1970, pp. 246.

(Received March 24, 1994; accepted April 25, 1994)